US Migraine Market

Approximately 28 million people in the United States live with migraine, with a prevalence of 18.2% among females and 6.5% among males. In a study, half of the participants reported that headaches were severe enough to affect their school and work productivity. With migraine costs estimated to be $13 to $17 billion per year in the United States alone, improved therapies to speed relief and reduce pain reduction are desirable.

The FDA has acknowledged the company’s proposed development strategy for its SUD-001 sumatriptan oral migraine spray.

This could accelerate registration of the treatment without requiring clinical studies by using a pharmacokinetic (PK) approach.

A BIG PARTNER looking to fast track product on behalf of SUDA is highly likely now given today's news. Look for a licensing deal, upfront payments and royalties in the future.